AcelRx Pharmaceuticals is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Co.'s portfolio include DSUVIA® and Zalviso®. DSUVIA, known as DZUVEO in Europe is indicated for use in adults in certified medically supervised healthcare settings, for the management of acute pain severe enough to require an opioid analgesic. Zalviso is a pre-programmed non-invasive system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. Zalviso is designed to help address certain problems associated with post-operative IV patient-controlled analgesia. We show 44 historical shares outstanding datapoints in our coverage of ACRX's shares outstanding history.
Understanding the changing numbers of ACRX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ACRX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ACRX by allowing them to research ACRX shares outstanding history
as well as any other stock in our coverage universe. |
Video: Shares Outstanding Importance
